Status:
COMPLETED
Efficacy of Different Acid Suppressors in Bismuth-containing Quadruple Therapy Against Helicobacter Pylori
Lead Sponsor:
Shandong University
Conditions:
Helicobacter Pylori; Eradication Rate
Eligibility:
All Genders
18-75 years
Brief Summary
Ａretrospective study was conducted to compare the efficacy, safety, and cost-effectiveness of traditional proton pump inhibitors (PPI ) and Potassium-competitive acid blockers ( P-CAB )for clarithromy...
Detailed Description
This study retrospectively enrolled participants with H. pylori infection who received bismuth quadruple regimen containing clarithromycin. The basic information, treatment results, adverse reactions ...
Eligibility Criteria
Inclusion
- Participants aged 18-75 years with persistent H. pylori infection.
- Participants received clarithromycin-based bismuth-containing quadruple therapy.
Exclusion
- Patients received rescue therapy
- Patients treated with PPI, P-CAB,bismuth and antibiotics in the previous 4 weeks
- Patients with gastorectomy
- Currently pregnant or lactating or other conditions unable to receive therapy
- Severe concomitant cardiovascular, respiratory, or endocrine diseases, clinically significant renal or hepatic disease, hematologic disorders and any other clinically significant medical condition that could increase risk
- Severe neurologic or psychiatric disorders
- Information incomplete
Key Trial Info
Start Date :
July 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
670 Patients enrolled
Trial Details
Trial ID
NCT05301725
Start Date
July 1 2018
End Date
December 31 2021
Last Update
March 31 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Qilu hosipital
Jinan, Shandong, China, 250012